Studienliste: Hämatologische Erkrankungen

Diagnosen

Hämatologische Erkrankungen, Kopf-Hals-Karzinom [C00-C14, C32], COVID-19 Infektion

Einschlusskriterien

Prinzipiell alle Patienten, die der Verwendung der Restproben zustimmen, das Formblatt unterschrieben haben und denen im Rahmen einer Routineuntersuchung Material (Blut, Knochenmark, Tumorgewebe, andere Gewebe) entnommen wird.

Kontaktpersonen

anastasia.navadeh-meshkat-divan@uk-koeln.de
joanna.wessel@uk-koeln.de
juergen.wolf@uk-koeln.de
thomas.zander@uk-koeln.de

Ausschlusskriterien

Diagnostische, epidemiologische und sonstige Prüfungen entfallen.

Diagnosen

Hämatologische Erkrankungen, Hämatoonkologische Erkrankungen [C81-C96], Chronische myeloische Leukämie [CML], BCR/ABL-positiv [C92.1], Polycythaemia vera [D45], Osteomyelofibrose [D47.4]

Einschlusskriterien

• MPN gemäß WHO-Kriterien
• Alter mindestens 18 Jahre

Kontaktpersonen

betuel.oezdemir@uk-koeln.de
c.scheid@uni-koeln.de
andreas.zueiter@uk-koeln.de

Ausschlusskriterien

• keine MPN
• Alter unter 18 Jahren

Diagnosen

Hämatologische Erkrankungen

Einschlusskriterien

Ausschlusskriterien

Diagnosen

Kinderonkologie und -hämatologie, Hämatologische Erkrankungen

Einschlusskriterien

Ausschlusskriterien

Diagnosen

Hämatologische Erkrankungen

Einschlusskriterien

Age ≥ 50 years old Presence of a hematologic malignancy for which an alloHCT is indicated with a reduced toxicity or reduced intensity conditioning regimen Patients with polynuclear neutrophils > 0.5 G/L Patients having received wide spectrum antibiotics within the last 90 days prior to inclusion Karnofsky index ≥ 70%

Ausschlusskriterien

Patients planned to receive a non-myeloablative conditioning regimen (2 Gray total body irradiation (TBI) +/- purine analog, fludarabine + cyclophosphamide or equivalent) Patients planned to receive a conventional myeloablative conditioning regimen (e.g. high dose cyclophosphamide and high dose TBI (≥10Gy); high dose busulfan (12.8 mg/kg IV) + high dose cyclophosphamide) Patients receiving a manipulated graft (in-vitro T-cell depletion) Patients planned to receive a conditioning regimen with alemtuzumab Patients planned to receive alloHCT with cord blood cells Patients planned to receive alloHCT from unrelated donor with >= 3/10 HLA-mismatches Patients receiving a large spectrum antibiotic at time of randomization

Diagnosen

Hämatologische Erkrankungen, Multiples Myelom [C90]

Einschlusskriterien

Auswahl: 1. Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF). 2. Subject has documented diagnosis of MM and measurable disease, defined as any of the following: a. M-protein ≥ 0.5 g/dL by serum protein electrophoresis (sPEP) or b. M-protein ≥ 200 mg/24-hour urine collection by urine protein electrophoresis (uPEP) or, c. For subjects without measurable disease in sPEP or uPEP: serum free light chain (sFLC) levels > 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda FLC ratio. 3. Subject has received 1 to 3 prior lines of antimyeloma therapy. (Note: One line can contain several phases [eg, induction, (with or without) hematopoietic stem cell transplant, (with or without) consolidation, and/or (with or without) maintenance therapy) See APPENDIX J. 4. Subject must have received prior treatment with a lenalidomide-containing regimen. 5. Subject must have documented disease progression during or after their last antimyeloma regimen.

Ausschlusskriterien

Auswahl: 1. Subject who has had progression during treatment or within 60 days of the last dose of a proteasome inhibitor. 2. For subjects with prior treatment of a bortezomib containing regimen, the best response achieved was not a minimal response (MR) or better, or subject discontinued bortezomib due to toxicity. 3. Subject has previously received allogeneic stem cell transplantation at any time during prior therapy or received autologous stem cell transplantation within 12 weeks of initiating study treatment.